Humacyte (HUMA) Common Equity (2020 - 2026)

Humacyte (HUMA) has 7 years of Common Equity data on file, last reported at $11.6 million in Q1 2026.

• Common Equity for Q1 2026 came in at $11.6 million, down 67.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.6 million (down 67.75% YoY), and the FY2025 annual result was $3.1 million, up 105.9% from the prior year.
• Common Equity climbed to $11.6 million in Q1 2026 per HUMA's latest filing, from $3.1 million in the prior quarter.
• Over five years, Common Equity peaked at $142.3 million in Q2 2022 and troughed at -$63.7 million in Q3 2024.
• A 5-year average of $35.7 million and a median of $26.2 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity soared 137.46% in 2022, then sank 488.82% in 2024.
• A 5-year view of Common Equity shows it stood at $116.9 million in 2022, then plunged by 88.42% to $13.5 million in 2023, then slumped by 488.82% to -$52.7 million in 2024, then soared by 105.9% to $3.1 million in 2025, then jumped by 273.88% to $11.6 million in 2026.
• Business Quant data shows HUMA's Common Equity at $11.6 million in Q1 2026, $3.1 million in Q4 2025, and -$4.8 million in Q3 2025.